KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Total Current Liabilities (2016 - 2025)

Gilead Sciences (GILD) has disclosed Total Current Liabilities for 17 consecutive years, with $11.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 1.59% year-over-year to $11.8 billion, compared with a TTM value of $11.8 billion through Dec 2025, down 1.59%, and an annual FY2025 reading of $11.8 billion, down 1.59% over the prior year.
  • Total Current Liabilities was $11.8 billion for Q4 2025 at Gilead Sciences, down from $12.3 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $14.0 billion in Q2 2023 and bottomed at $8.6 billion in Q1 2022.
  • Average Total Current Liabilities over 5 years is $11.2 billion, with a median of $11.3 billion recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 51.45% in 2023, then decreased 22.79% in 2024.
  • Year by year, Total Current Liabilities stood at $11.6 billion in 2021, then fell by 3.21% to $11.2 billion in 2022, then grew by 0.38% to $11.3 billion in 2023, then grew by 6.42% to $12.0 billion in 2024, then decreased by 1.59% to $11.8 billion in 2025.
  • Business Quant data shows Total Current Liabilities for GILD at $11.8 billion in Q4 2025, $12.3 billion in Q3 2025, and $11.2 billion in Q2 2025.